Adagene Bolsters Leadership with Oncology Veteran Lebowitz
Event summary
- Adagene appointed Peter Lebowitz, former Global Head of Oncology R&D at Johnson & Johnson, to its Scientific and Strategic Advisory Board (SAB).
- Lebowitz previously oversaw a research and development organization at J&J that delivered 13 new drugs and secured 12 FDA Breakthrough Therapy Designations.
- Lebowitz's focus will be on guiding the clinical development of Adagene's lead program, ADG126, particularly strategies for registration-enabling studies.
- ADG126 is a masked anti-CTLA-4 SAFEbody in Phase 1b/2 and Phase 2 trials for MSS metastatic colorectal cancer (CRC).
The big picture
Adagene's acquisition of Lebowitz signals a strategic push to accelerate the clinical development of its ADG126 program and expand the application of its SAFEbody technology. The company is attempting to address a significant unmet need in MSS CRC, where existing immunotherapies have shown limited efficacy. Lebowitz's track record of successfully navigating drug development and regulatory hurdles will be crucial for Adagene's success in a competitive oncology landscape.
What we're watching
- Clinical Efficacy
- The success of ADG126 in MSS CRC, a historically difficult-to-treat cancer, will be critical to validating Adagene's SAFEbody platform and attracting further investment.
- Regulatory Pathway
- Lebowitz’s experience will be tested as Adagene navigates registration-enabling studies; the FDA’s acceptance of Adagene’s novel masking approach could set a precedent for future immunotherapy development.
- Platform Expansion
- Adagene’s ability to leverage the SAFEbody platform beyond ADG126, particularly in combination therapies, will determine the long-term value of the technology.
Related topics